Arjo AB (FRA:A39) Stock Based Compensation: €0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A39 Arjo AB FRA:A39
74 GF Score
Price €2.44
GF Value €3.10
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Arjo AB Stock Based Compensation?

Arjo AB FRA:A39 +0.58% 74 Stock Based Compensation is €0 Mil as of Jun. 2026. GuruFocus rates FRA:A39 with a GF Score™ of 74/100 and a GF Value™ of €3.10 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Arjo AB's Stock Based Compensation for the three months ended in Jun. 2026 was €0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €0 Mil.

Arjo AB Stock Based Compensation Related Terms

Arjo AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Arjo AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arjo AB Stock Based Compensation Chart

Arjo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arjo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:A39
74GF Score
Arjo AB FRA:A39
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arjo AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

What does a Stock Based Compensation of €0 Mil mean?
Arjo AB (FRA:A39) has a Stock Based Compensation of €0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Arjo AB and its competitors.
Is Arjo AB's Stock Based Compensation too high?
Arjo AB's current Stock Based Compensation is €0 Mil. Overall, Arjo AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Stock Based Compensation compare to MCK and CAH?
Arjo AB's Stock Based Compensation of €0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Distribution company?
A good Stock Based Compensation depends on the Medical Distribution industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Arjo AB and its competitors. Arjo AB's current Stock Based Compensation is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.10, compared to a current price of €2.44 — trading 21.4% below its estimated fair value. The current Stock Based Compensation is €0 Mil. Arjo AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current Stock Based Compensation is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arjo AB (FRA:A39) Overvalued in 2026?

Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued. The current stock price of €2.44 is trading 21.4% below its estimated GF Value™ of €3.10. GuruFocus considers Arjo AB to be Modestly Undervalued.

Key valuation signals for FRA:A39:

  • Stock Based Compensation: €0 Mil
  • GF Value™: €3.10 vs. price of €2.44 (21.4% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arjo AB Business Description

Address Hans Michelsensgatan 10, Box 48, Malmo, SWE, SE-201 20
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score

Get the complete analysis for FRA:A39

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price
€3.10
GF Value